Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Clinical trial NCT06125652 · RECRUITING

Trial details

NCT number: NCT06125652
Sponsor: Xuzhou Medical University
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia, in Relapse

Start date: 2023-11-04
Primary completion: 2026-01-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.